Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AIDX

20/20 Biolabs Inc

0.5698

Jul 13 • 03:59PM ET -0.0193 (-3.28%)

0.5630

Aftermarket • 07:50PM ET -0.0068 (-1.19%)

Healthcare Medical Devices USA Nano NASD

Peers: ADGM ICCM IRIX NXL PMI SINT TRIB VVOS XAIR NUWE

Scroll to Statements

Index	-
Market Cap	6.98M
Enterprise Value	3.89M
Income	-
Sales	-
Book/sh	0.24
Cash/sh	0.34
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	14
IPO	Feb 19, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.33
P/C	1.65
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.78
Current Ratio	1.82
Debt/Eq	0.34
LT Debt/Eq	0.16
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-0.38
EPS next Q	-0.12
EPS this Y	44.74%
EPS next Y	9.52%
EPS next 5Y	17.29%
EPS past 3/5Y	- 3.60%
Sales past 3/5Y	-43.03% -2.58%
EPS Y/Y TTM	4.55%
Sales Y/Y TTM	-
EPS Q/Q	47.92%
Sales Q/Q	-2.11%
Earnings	May 20 AMC
EPS/Sales Surpr.	-180.00% -54.63%

Insider Own	33.61%
Insider Trans	0.00%
Inst Own	2.45%
Inst Trans	34.63%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-7.60%
SMA50	-39.85%
SMA200	-72.48%
Trades

Shs Outstand	10.44M
Shs Float	8.13M
Short Float	2.30%
Short Ratio	0.23
Short Interest	0.19M
52W High	50.00 -98.86%
52W Low	0.51 11.49%
Volatility	8.92% 13.00%
ATR (14)	0.10
RSI (14)	32.95
Beta	-
Rel Volume	0.21
Avg Volume	800.77K
Volume	165,383

Perf Week	-8.69%
Perf Month	-34.46%
Perf Quarter	-69.69%
Perf Half Y	-
Perf YTD	-98.86%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	5.00
Prev Close	0.59
Price	0.57
Change	-3.28%

Jul-09-26 04:01PM	20/20 BioLabs Highlights Investor Webinar Focused on OneTest for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth (GlobeNewswire)
Jun-22-26 04:45PM	20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month (GlobeNewswire) -6.85%
May-27-26 08:31AM	20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters (GlobeNewswire)
May-22-26 08:31AM	20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand (GlobeNewswire) -18.67%
May-20-26 04:05PM	20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress (GlobeNewswire) -6.59%
07:30AM	Loading…
07:30AM	Sidoti Events, LLC's May Micro-Cap Virtual Conference (ACCESSWIRE)
May-14-26 08:31AM	20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026 (GlobeNewswire)
May-12-26 08:31AM	20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina (GlobeNewswire) +6.33%
Apr-13-26 07:00AM	HEALWELL to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference (TMX Newsfile)
Apr-07-26 08:31AM	20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest for Cancer Through Evexia Platform (GlobeNewswire) -5.45%
Mar-31-26 04:57PM	20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress (GlobeNewswire) +5.62%
Mar-27-26 08:31AM	Maryland Fire Departments Awarded $520,000 for Cancer Screenings using 20/20 BioLabs' OneTest Multi-Cancer Early Detection Blood Test (GlobeNewswire)
Mar-24-26 08:31AM	20/20 BioLabs Announces Exclusive U.S. License Agreement with ROKIT Healthcare to Integrate Advanced CKD Prediction Technology into Its Longevity Test Program (GlobeNewswire) -17.59%
Mar-19-26 07:00AM	HEALWELL AI Delivers Record Revenue and First Year of Positive Adjusted EBITDA as Global AI Platform Strategy Takes Hold (TMX Newsfile) -5.05%
Mar-12-26 08:31AM	20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies (GlobeNewswire) -8.49%
08:31AM	Loading…
Feb-25-26 08:31AM	20/20 BioLabs Launches OneTest for Longevity Blood Test and Chronic Disease Risk Assessment and Management Solution Built with IBM AI Capabilities (GlobeNewswire) -28.82%
Feb-20-26 08:31AM	20/20 BioLabs to Host Virtual Investor Webinar on Thursday, February 26, 2026 at 2:00 p.m. Eastern Time (GlobeNewswire) -38.04%
Feb-19-26 09:00AM	20/20 BioLabs Debuts Trading on Nasdaq Under Ticker Symbol "AIDX" Following 3 Consecutive Years of Sales Growth (GlobeNewswire)

20/20 Biolabs, Inc. engages in development and commercialization of proteomics product line. Its products include One Test, PAULA's Test and BioCheck Suspisious Powder Testing Kit. The company was founded by Jonathan Cohen in May 2000 and is headquartered in Gaithersburg, MD.

FounderMr. Jonathan Cohen

Chief Operating OfficerDr. Jiming Zhou Ph.D.

Chief Scientific OfficerDr. Michael Saul Lebowitz Ph.D.

Chief Financial OfficerMr. Alan B. Bergman

Director of SalesMr. David Lees

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AIDX

20/20 Biolabs Inc

Upgrade your Finviz experience